Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1XT4N)

• Drug Name: Tafenoquine Drug Info
• Synonyms: 106635-80-7; WR-238605; WR 238605; Etaquine; WR238605; Tafenoquine [INN:BAN

Indication

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[1]
Plasmodium vivax malaria	1F41	Approved	[1]

• Cross-matching ID:
  PubChem CID: 115358
  ChEBI ID: CHEBI:141487
  CAS Number: CAS 106635-80-7
  TTD Drug ID: DM1XT4N
  INTEDE Drug ID: DR1526
  ACDINA Drug ID: D01454

Molecule-Related Drug Atlas

Drug(s) Targeting Reactive oxygen species (ROS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Procysteine	DMF9RB4	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[3]
Mitoquinone	DMKPZ0Q	Hepatitis C virus infection	1E51.1	Phase 2	[4]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[5]

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[6]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[7]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[8]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[9]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[11]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[12]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[13]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[14]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Electron transport complex III (Complex III)	TTB8JQ7	CY1_HUMAN-CYB_HUMAN	Inhibitor	[1]
Reactive oxygen species (ROS)	TTULV0X	NOUNIPROTAC	Modulator	[1]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[2]

References

• [1] Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523.
• [2] Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99.
• [3] Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions. J Antimicrob Chemother. 2013 Oct;68(10):2305-10.
• [4] Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192.
• [5] A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35.
• [6] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [7] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [8] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [9] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [10] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [11] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [12] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [13] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [14] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [15] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.